Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZEJULA vs LYNPARZA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, including PARP1, PARP2, and PARP3. Inhibits PARP catalytic activity and traps PARP-DNA complexes, leading to accumulation of DNA damage and apoptosis in BRCA-deficient tumor cells.
Poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, including PARP1, PARP2, and PARP3. Inhibits PARP catalytic activity and traps PARP-DNA complexes, leading to replication fork stalling, double-strand breaks, and cell death in tumors with homologous recombination repair deficiencies such as BRCA mutations.
Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy,Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy (FDA-approved),Maintenance treatment of recurrent ovarian cancer (off-label for other PARP inhibitors combination)
FDA-approved for maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (g BRCAm) advanced ovarian cancer after response to first-line platinum-based chemotherapy,FDA-approved for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy,FDA-approved for treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma after at least 16 weeks of a first-line platinum-based chemotherapy regimen,FDA-approved for treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative metastatic breast cancer after prior chemotherapy; in the setting of hormone receptor-positive breast cancer, after prior endocrine therapy,FDA-approved for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status,Off-label use: treatment of recurrent prostate cancer with homologous recombination repair gene mutations
300 mg orally once daily with or without food.
300 mg orally twice daily, with or without food.
36 ± 13 hours; supports twice-daily dosing; in moderate hepatic impairment (Child-Pugh B), t1/2 prolonged to 58 hours.
The terminal elimination half-life is approximately 14.9 hours in patients with advanced solid tumors. This supports twice-daily dosing to maintain therapeutic concentrations.
Primarily metabolized by carboxylesterases (CES1 and CES2) to yield M1 and M2 metabolites; undergoes further glucuronidation via UGT1A1 and UGT1A3. Niraparib inhibits BCRP and P-glycoprotein (P-gp) transporters. Minimal CYP-mediated metabolism.
For GFR ≥30 m L/min, no adjustment; for GFR <30 m L/min, not recommended.
For creatinine clearance 31-60 m L/min: 300 mg twice daily; for creatinine clearance 16-30 m L/min: 200 mg twice daily; for creatinine clearance ≤15 m L/min: not recommended.
Child-Pugh A: 300 mg once daily; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended.
None
ZEJULA (niraparib) is embryotoxic and teratogenic in animal studies. Based on its mechanism of action (PARP inhibition), it can cause fetal harm when administered to a pregnant woman. First trimester exposure carries highest risk for major congenital malformations. Second and third trimester exposure may lead to fetal growth restriction and oligohydramnios. There are no adequate human data; however, animal studies demonstrate embryofetal toxicity at exposures below human therapeutic levels.
Based on its mechanism of action (PARP inhibition) and animal studies, olaparib is embryotoxic and teratogenic. It is contraindicated in pregnancy. There is a potential for fetal harm in all trimesters due to genotoxicity and effects on rapidly dividing cells.
ZEJULA (niraparib) is a PARP inhibitor indicated for maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Assess for myelosuppression monthly; thrombocytopenia is common. Monitor blood pressure for hypertension, especially in the first year. Consider dose reduction for baseline moderate hepatic impairment. Avoid use with strong CYP3A4 inducers.
Lynparza (olaparib) is a PARP inhibitor indicated for maintenance therapy in BRCA-mutated advanced ovarian cancer, HER2-negative metastatic breast cancer with germline BRCA mutation, pancreatic cancer with germline BRCA mutation, and metastatic castration-resistant prostate cancer with homologous recombination repair gene mutations. Monitor for myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with baseline and periodic blood counts. Discontinue if MDS/AML is confirmed. Assess renal function before initiation; reduce dose for moderate renal impairment (Cr Cl 30-50 m L/min). Avoid concurrent use with strong CYP3A4 inhibitors or inducers. Monitor for pneumonitis and venous thromboembolic events. For hormone receptor-positive breast cancer, administer with a gonadotropin-releasing hormone agonist or in patients who are postmenopausal.
No interactions on record
No interactions on record
ZEJULA and LYNPARZA are distinct pharmacological agents. ZEJULA belongs to the PARP Inhibitor class and is primarily used for Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapyMaintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy (FDA-approved)Maintenance treatment of recurrent ovarian cancer (off-label for other PARP inhibitors combination). LYNPARZA belongs to the PARP inhibitor class and is primarily used for FDA-approved for maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer after response to first-line platinum-based chemotherapyFDA-approved for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapyFDA-approved for treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma after at least 16 weeks of a first-line platinum-based chemotherapy regimenFDA-approved for treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative metastatic breast cancer after prior chemotherapy; in the setting of hormone receptor-positive breast cancer, after prior endocrine therapyFDA-approved for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive statusOff-label use: treatment of recurrent prostate cancer with homologous recombination repair gene mutations. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. ZEJULA carries a safety status of Category C, whereas LYNPARZA safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily metabolized by CYP3A4; minor contributions from CYP3A5.
Renal: 70.9% (11.1% unchanged); fecal: 15.5%; metabolism via carboxylesterases (CES1/CES2) and renal excretion of metabolites.
Following oral administration of olaparib, approximately 70% of the dose is recovered in feces (44% as unchanged parent drug) and 16% in urine (1% as unchanged drug). Biliary excretion is the primary route of elimination, with renal excretion playing a minor role.
83% bound to human plasma proteins (mainly albumin and α1-acid glycoprotein).
Approximately 82% bound to human plasma proteins, primarily to albumin.
74.7 L (approx. 1.06 L/kg for 70 kg); indicates extensive tissue distribution.
The apparent volume of distribution (Vd/F) is approximately 158 L (about 2.2 L/kg for a 70 kg patient), indicating extensive distribution into tissues.
73% following oral administration (capsule, fed or fasted).
Oral bioavailability is not precisely defined in humans due to lack of IV formulation; however, based on animal data and clinical pharmacokinetics, oral absorption is rapid and extensive, with peak plasma concentrations achieved 1-3 hours post-dose. Food does not significantly affect absorption.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 300 mg twice daily (caution); Child-Pugh Class C: not recommended.
Safety and efficacy not established in pediatric patients.
Not established; safety and efficacy not determined in patients <18 years.
No specific dose adjustment recommended; consider age-related renal function decline.
No specific dose adjustment based on age alone; monitor renal function and adjust per renal guidelines.
None
Avoid grapefruit and grapefruit juice. No other known food interactions. Can be taken with or without food.
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit during treatment as they inhibit CYP3A4 and may increase olaparib exposure. No other food restrictions; may take with or without food.
No data available on niraparib presence in human milk, effects on breastfed infants, or milk production. Due to potential for serious adverse reactions in nursing infants from this antineoplastic agent, breastfeeding is contraindicated during therapy and for 1 month after the last dose. M/P ratio unknown.
No data on presence in human milk. Due to potential serious adverse reactions in breastfed infants (genotoxicity, developmental toxicity), breastfeeding is not recommended during treatment and for 1 month after the last dose. M/P ratio unknown.
No established dose adjustment in pregnancy. ZEJULA is contraindicated in pregnancy; alternative therapy should be considered. If used, monitor for decreased drug exposure due to increased plasma volume and altered hepatic metabolism potentially requiring dose increase, but no data available. Use lowest effective dose if unavoidable.
No dose adjustments are recommended as olaparib is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are not studied; therefore, use during pregnancy is not advised.
Take ZEJULA once daily at the same time, with or without food. Swallow capsules whole.,Report any new or worsening shortness of breath, chest pain, or leg swelling (risk of hypertension and cardiac events).,Notify your doctor immediately if you experience easy bruising, bleeding, or signs of infection (fever, sore throat) due to possible low blood counts.,Use effective contraception during treatment and for at least 6 months after the last dose because ZEJULA can harm a fetus.,Avoid drinking grapefruit juice or eating grapefruit while taking ZEJULA.,Do not breastfeed while taking ZEJULA and for at least 1 month after the last dose.
Take Lynparza exactly as prescribed, usually twice daily with or without food. Swallow capsules whole; do not crush or chew.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while taking Lynparza as they may interact.,Inform your doctor immediately if you experience unusual bruising, bleeding, fever, fatigue, or shortness of breath, which may indicate bone marrow problems.,Use effective contraception during treatment and for at least 6 months after the last dose. Do not breastfeed during treatment.,Keep all appointments for blood tests to monitor blood cell counts and kidney function.,Report new or worsening shortness of breath, cough, or fever as these could be signs of lung inflammation.,Avoid taking other medications, including over-the-counter drugs, without consulting your doctor due to potential drug interactions.,Lynparza may cause fatigue; do not drive or operate machinery if feeling dizzy or tired.